SERONO, INC. AND NEWRON PHARMACEUTICALS ANNOUNCE GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR SAFINAMIDE

Serono and Newron Pharmaceuticals SpA, announced today an agreement under which Newron has granted Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in Parkinson's disease (PD), Alzheimer's disease, and other cognitive disorders. Newron has recently reported positive results with safinamide from an early Phase III study in Parkinson's disease. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=33182&full=1)